# A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

> **NCT03188185** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 278 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** ALKS 5461
- **DRUG:** ALKS 5461 Placebo

## Key facts

- **NCT ID:** NCT03188185
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2020-02-26
- **Final completion:** 2020-03-05
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188185, "A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03188185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*